Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006734 · ClinicalTrials.gov registry record · Phase 3

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

A Phase 3 study of Sarcoma, sponsored by Children's Oncology Group.

Completed
Registry status
Phase 3
Development phase
587
Enrollment target
20
Study locations

NCT00006734 is a Phase 3 study of Sarcoma that has completed, run by Children's Oncology Group. The registered enrollment target is 587 participants, below the 916-participant average among 122 other Sarcoma trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006734, a Phase 3 study of Sarcoma, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase
587 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor. PURPOSE: Randomized phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy and/or surgery in treating patients who have Ewing's sarcoma or primitive neuroectodermal tumor.

Conditions Studied

Interventions

  • DRUG cyclophosphamide
  • DRUG etoposide
  • DRUG ifosfamide
  • BIOLOGICAL filgrastim
  • DRUG doxorubicin hydrochloride

Study Locations (20)

California

  • Southern California Permanente Medical Group - Downey
  • City of Hope Comprehensive Cancer Center - Duarte
  • Rebecca and John Moores UCSD Cancer Center - La Jolla
  • Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
  • Jonathan Jaques Children's Cancer Center at Miller Children's Hospital - Long Beach
  • Children's Hospital Los Angeles - Los Angeles
  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center - Los Angeles
  • Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
  • Children's Hospital Central California - Madera
  • Children's Hospital and Research Center at Oakland - Oakland
  • Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center - Orange
  • Children's Hospital of Orange County - Orange
  • Lucile Packard Children's Hospital at Stanford University Medical Center - Palo Alto
  • Sutter Cancer Center - Sacramento
  • University of California Davis Cancer Center - Sacramento

Alabama

  • Comprehensive Cancer Center at University of Alabama at Birmingham - Birmingham
  • University of South Alabama Cancer Research Institute - Mobile

Arizona

  • Phoenix Children's Hospital - Phoenix
  • Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 587 participants
Start Date 2001-05
Est. Completion 2023-06-30
Phase Phase 3

Sponsor

Children's Oncology Group

342 total trials

What the Registry Record Tells You About NCT00006734

The ClinicalTrials.gov registry entry for NCT00006734 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 587 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 916-participant average among 122 other Sarcoma trials with a reported enrollment target (36% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.

NCT00006734 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00006734 about?

NCT00006734 is a clinical study titled "Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective...

What is the current status of trial NCT00006734?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 587 participants. The study started on 2001-05. Estimated completion is 2023-06-30.

What conditions does trial NCT00006734 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT00006734?

The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00006734?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006734 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.